Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 2 · 28.6%High 1 · 14.3%

Anti‐TNF discontinuation vs anti‐TNF continuation

Proportion participants that switched to another biologic due to loss of response ‐ not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐TNF discontinuation vs anti‐TNF continuation

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation leads to higher proportion participants with minimal radiographic progression compared with anti‐TNF continuation (high certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.69 [1.1, 2.59]
3 studies · 549 participants
High

Anti‐TNF discontinuation vs anti‐TNF continuation

Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1498 participants
Low

Anti‐TNF discontinuation vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.29 [0.82, 2.03]
8 studies · 2095 participants
Very low

Anti‐TNF discontinuation vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.46 [0.75, 2.84]
4 studies · 1116 participants
Moderate

Anti‐TNF discontinuation vs anti‐TNF continuation

Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 733 participants
Moderate

Anti‐TNF discontinuation vs anti‐TNF continuation

Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation may leads to lower proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1188 participants
Low